納斯達克迎生技IPO密集週: Attovia、Braveheart Bio Vogenx合計最高募資逾6.1億美元

美股生技IPO市場於本週迎來一輪密集發行。三家仍處臨床開發階段的創新生物製藥企業——Attovia Therapeutics、Braveheart Bio及Vogenx——目前分別安排於2026年8月5日至6日登陸納斯達克。按照招股價格區間上限計算，三家公司合計最高募資規模約6.125億美元；按區間中位數計算，合計募資約5.75億美元。最終發行價格、募資額與掛牌時間仍可能因市場狀況而調整。

Attovia Therapeutics：多特異性生物藥平台切入免疫疾病

Attovia Therapeutics計劃以代號ATTO上市，擬發行1,250萬股，每股價格區間15至17美元，預計募資約1.875億至2.125億美元。

公司透過由Alamar Biosciences授權的ATTOBODY平台，開發針對免疫介導疾病的單特異性及多特異性生物藥。其領先候選藥ATTO-1310靶向被稱為「搔癢細胞因子」的IL-31，已於2026年第一季完成健康受試者，以及慢性搔癢和高搔癢型異位性皮膚炎患者的第一期臨床給藥。公司披露的初步數據顯示，候選藥具快速緩解搔癢及延長給藥間隔的潛力。

截至2026年3月31日，Attovia持有現金、現金等價物及有價證券約1.326億美元；2026年第一季淨虧損約1,870萬美元。IPO資金主要將投入ATTO-1310

ATTO-2306的中期臨床開發，以及ATTO-1091的早期臨床推進。

Braveheart Bio：恒瑞授權心血管資產成為本週最大生技IPO

Braveheart Bio計劃以代號BRVE上市，擬發行1,875萬股，每股價格區間15至17美元，按中位數計算募資約3億美元，是三家公司中規模最大的一宗IPO。按價格區間上限計算，其募資額可達約3.1875億美元。

公司核心資產BHB-1893是一款口服小分子心肌肌球蛋白抑制劑，最初由江蘇恒瑞醫藥發現及開發。Braveheart於2025年9月取得中國內地、香港、澳門及台灣以外地區的相關開發和商業化權利，計劃分別用於阻塞型與非阻塞型肥厚型心肌病。

Fidelity Management & Research已表達最高認購7,500萬美元IPO股份的意向，反映專業機構對該資產的關注，但相關認購意向並不構成具約束力的承諾。

Vogenx：單一核心資產押注餐後代謝失衡

Vogenx計劃以代號VOGX上市，擬發行625萬股，每股價格區間11至13美元，預計募資約6,875萬至8,125萬美元。

其核心候選藥mizagliflozin是一款口服、低全身吸收的選擇性SGLT1抑制劑，作用於腸道葡萄糖轉運機制。該藥物最初由日本Kissei Pharmaceutical發現，Vogenx取得日本、韓國及台灣以外的全球獨家權利。

市場觀察

本週三宗生技IPO反映，美股初級市場正在重新向具備明確臨床催化劑、專業機構股東及差異化資產的臨床階段企業開放。然而，這並不代表生技板塊已全面恢復高估值融資，而是資本更集中於作用機制清晰、臨床路徑明確，以及能在短期內產生關鍵數據的資產。

本輪IPO更適合作為市場對臨床資產質量及風險承受能力的測試，而不能僅以募資規模判斷企業的長期投資價值。最終定價、機構配售情況、上市首日表現，以及上市後首批臨床數據，將成為評估本輪生技IPO窗口能否延續的重要指標。

投資風險提示

本文僅供市場資訊交流及產業趨勢分析，不構成任何證券買賣、估值判斷或投資建議。臨床階段生技企業普遍具有研發週期長、監管審批不確定、商業化投入龐大及持續融資需求高等特徵。任何臨床試驗失敗、安全性事件、監管延誤或資本市場環境轉弱，均可能導致公司估值及股價大幅波動。投資人應獨立評估相關風險並自行承擔投資結果。

Nasdaq Prepares for a Heavy Biotech IPO Week: Attovia, Braveheart Bio, and Vogenx Target Over $610M in Combined Proceeds

The U.S. biotechnology IPO market is set for a heavy slate of offerings this week. Three clinical-stage biopharmaceutical companies—Attovia Therapeutics, Braveheart Bio, and Vogenx—are scheduled to debut on the Nasdaq between August 5 and August 6, 2026. Based on the upper bound of their proposed price ranges, the three companies aim to raise a combined total of approximately $612.5 million, or roughly $575 million based on the midpoint. Final pricing, total proceeds, and listing timelines remain subject to market conditions.

Attovia Therapeutics: Leveraging a Multispecific Biologics Platform for Immunological Diseases

Attovia Therapeutics plans to list under the ticker symbol ATTO, offering 12.5 million shares at an estimated price range of $15 to $17 per share, targeting gross proceeds of approximately $187.5 million to $212.5 million.

The company utilizes its proprietary ATTOBODY platform—licensed from Alamar Biosciences—to develop monospecific and multispecific biologics targeting immune-mediated diseases. Its lead candidate, ATTO-1310, targets IL-31 (commonly known as the "pruritus cytokine"). In the first quarter of 2026, the company completed dosing in healthy volunteers and patients with chronic pruritus and high-pruritus atopic dermatitis in Phase 1 trials. Preliminary data disclosed by the company indicate potential for rapid itch relief and extended dosing intervals.

As of March 31, 2026, Attovia held approximately $132.6 million in cash, cash equivalents, and marketable securities, with a net loss of roughly $18.7 million in the first quarter of 2026. Proceeds from the IPO will primarily fund the mid-stage clinical development of ATTO-1310 and ATTO-2306, as well as the early-stage advancement of ATTO-1091.

Braveheart Bio: In-Licensed Cardiovascular Asset from Hengrui Anchors the Week's Largest Biotech IPO

Braveheart Bio plans to list under the ticker symbol BRVE, offering 18.75 million shares at a price range of $15 to $17 per share. Based on the midpoint, the company targets approximately $300 million in proceeds, representing the largest offering among the three. At the upper end of the price range, total proceeds could reach approximately $318.75 million.

The company's core asset is BHB-1893, an oral small-molecule cardiac myosin inhibitor originally discovered and developed by Jiangsu Hengrui Pharmaceuticals. In September 2025, Braveheart acquired development and commercialization rights for the asset globally, excluding mainland China, Hong Kong, Macau, and Taiwan, with intended indications for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).

Fidelity Management & Research has indicated an interest in purchasing up to $75 million of shares in the offering, underscoring institutional interest in the asset, though this expression of interest does not constitute a binding commitment.

Vogenx: A Single-Asset Play on Postprandial Metabolic Imbalance

Vogenx plans to list under the ticker symbol VOGX, offering 6.25 million shares at a price range of $11 to $13 per share, anticipating gross proceeds of approximately $68.75 million to $81.25 million.

Its lead candidate, mizagliflozin, is an oral, low-systemic-exposure, selective SGLT1 inhibitor that acts on intestinal glucose transport mechanisms. Originally discovered by Kissei Pharmaceutical, Vogenx holds exclusive global rights outside of Japan, South Korea, and Taiwan.

Market Observations

The three biotech IPOs slated for this week indicate that the primary U.S. equities market is selectively reopening to clinical-stage companies featuring clear clinical catalysts, institutional backing, and differentiated assets. However, this does not signal a broad-based recovery in high-valuation biotech financing; rather, capital is concentrating heavily on assets with validated mechanisms of action, well-defined clinical pathways, and near-term catalysts capable of generating pivotal data.

This cohort of IPOs serves more as a litmus test for market appetite regarding clinical asset quality and risk tolerance, rather than a broad indicator of long-term enterprise value based solely on deal size. Final pricing, institutional book building, aftermarket performance, and incoming clinical readouts will serve as critical benchmarks for the sustainability of the current biotech issuance window.

Investment Risk Disclosure

This material is provided strictly for market information exchange and industry trend analysis and does not constitute a recommendation, valuation judgment, or solicitation to buy or sell any securities. Clinical-stage biopharmaceutical companies inherently exhibit long research and development cycles, regulatory approval uncertainties, substantial commercialization expenditures, and ongoing capital requirements. Any clinical trial failures, adverse safety events, regulatory delays, or deterioration in macroeconomic and capital market conditions may result in significant volatility in company valuations and share prices. Investors should independently evaluate relevant risks and assume full responsibility for their investment outcomes.

https://www.ivy-service.com

alinson@ivy-service.com